Medistem Laboratories OTCBB MEDS

Medistem’s mission is to discover, develop and commercialize technologies related to adult stem cell extraction and manipulation for use in treating inflammatory and degenerative diseases. The company has a portfolio of products in various stages of development covered by 15 families of patent applications.

The company has developed a novel type of stem cell, the Endometrial Regenerative Cell (ERC) that appears to have the major attributes desirable in an ideal cellular therapy: a) They are derived from non-controversial sources; b) The activity of the cells is not substantially neutralized by the immune system, allowing for use of cells from one standardized source (e.g. universal donor); c) The cells can be administered intravenously since they home to injured or degenerated tissue.

Medistem scientists demonstrated that ERC’s are capable of transforming into major tissues of the body including heart, lung, liver, brain, and blood vessels. It was published that ERC’s also produce large amounts of therapeutic factors, in some situations at higher levels than other types of stem cells. Medistem collaborators have demonstrated that ERC’s are potent inducers of new blood vessel formation in animals lacking proper circulation. To date studies have demonstrated that ERC’s do not cause adverse effects when administered at therapeutically-relevant doses to animals.

Medistem plans to enter clinic trials using ERC’s for a condition that will demonstrate proof of concept and safety in a rapid and cost effective way.